neobookRx
GuidelinesOther guideline

References

These are the approved guidelines published by the South African Society of Psychiatrists to provide an overview on treatment and management of commonly diagnosed psychiatric illnesses. The guidelines include consensus recommendations, based on peer contribution and using the international evidence based guidelines that are suitable for the local South African health service.

Please note that parts of this guideline may be out of date, an update will be published as soon as it is available.

  1. Jones PB, Barnes TRE, Davies L, et al. Randomised control trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1086. [http://dx.doi.org/10.1001/archpsyc.63.10.1079]

  2. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global burden of disease study. Lancet 1997;349:1436-1442. [http://dx.doi.org/10.1016/S0140-6736(96)07495-8]

  3. Brown S, Inskip H, Barraclough B. Causes of excess mortality of schizophrenia. Br J Psychiatry2000;177:212-217. [http://dx.doi.org/10.1192/bjp.177.3.212]

  4. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World Journal of Biological Psychiatry 2005;6:132-191. [http://dx.doi.org/10.1080/15622970510030090] 

  5. Lieberman JA, Scott Stroup T, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. [http://dx.doi.org/10.1056/NEJMoa051688]

  6. National Institute for Health and Clinical Excellence (NICE). Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care.London: NICE, 2009: Clinical Guidance 82. (http://www.nice.org.uk/guidance/index.isp?action=bvID&o=11786)

  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American PsychiatricAssociation, 2000.

  8. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009;373:31-41. [http://dx.doi.org/10.1016/S0140-6736(08)61764-X]

  9. Fleischhacker WW. Second generation antipsychotics. Psychopharmacology 2002;162:90-91.[http://dx.doi.org/10.1007/s00213-002-1064-8]

  10. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 2004;161:1-114.

  11. Kenneth O, Jobson MD. The International Psychopharmacology Algorithm Project (IPAP)- Schizophrenia Algorithm, Schizophrenia Algorithm nodes. 2006. http://www.ipap.org/(accessed July 2013).

  12. Crossley NA, Constante M, MacGuire P, et al. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: Meta-analysis. Br J Psychiatry 2010;196:434-439. [http://dx.doi.org/10.1192/bjp.bp.109.066217]

  13. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-163. [http://dx.doi.org/10.1176/appi.ajp.2008.08030368]

  14. Kane JM, Leucht S, Carpenter D, et al. The Expert Consensus Guideline Series: Optimising pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64:1-100.

  15. Gibbon CJ, Blockman M. South African Medicines Formulary, 8th ed. Cape Town: Health and Medical Publishing Group, South African Medical Association, 2008.

  16. Kissling W. Guidelines for neuroleptic relapse prevention in schizophrenia. 1991. Berlin:Springer, 1991.

  17. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry 2006;7:5-40. [http://dx.doi.org/10.1080/15622970500483177]

  18. Citrome L, Casey DE, Daniel DG, et al. Adjunctive divalproex and hostility among patientswith schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004;55:290-294.[http://dx.doi.org/10.1176/appi.ps.55.3.290]

  19. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: A systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2004;65:177-186. [http://dx.doi.org/10.4088/JCP.v65n0206]

Drugs mentioned

NeoHealth® ID 19845 · updated 4/20/2022